Cargando…
Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
BACKGROUND: No observational studies have evaluated the “real-world” effectiveness of dual bronchodilation comprising a long-acting β(2)-agonist plus a long-acting muscarinic antagonist vs that of triple therapy (long-acting β(2)-agonist plus long-acting muscarinic antagonist plus inhaled corticoste...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113909/ https://www.ncbi.nlm.nih.gov/pubmed/30197512 http://dx.doi.org/10.2147/COPD.S169958 |